MA26573A1 - Composes agonistes ou antagonistes du recepteur de l'orphanine, procede de preparation et medicament les contenant - Google Patents

Composes agonistes ou antagonistes du recepteur de l'orphanine, procede de preparation et medicament les contenant

Info

Publication number
MA26573A1
MA26573A1 MA25369A MA25369A MA26573A1 MA 26573 A1 MA26573 A1 MA 26573A1 MA 25369 A MA25369 A MA 25369A MA 25369 A MA25369 A MA 25369A MA 26573 A1 MA26573 A1 MA 26573A1
Authority
MA
Morocco
Prior art keywords
preparation
receptor agonist
medicament containing
antagonist compounds
orphanin
Prior art date
Application number
MA25369A
Other languages
English (en)
Inventor
Adam Geo
Cesura Andrea
Galley Guido
Jenck Francois
Rover Stephan
Wichmann Jurgen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26573A1 publication Critical patent/MA26573A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Color Printing (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA25369A 1997-12-05 1998-12-04 Composes agonistes ou antagonistes du recepteur de l'orphanine, procede de preparation et medicament les contenant MA26573A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97121427 1997-12-05

Publications (1)

Publication Number Publication Date
MA26573A1 true MA26573A1 (fr) 2004-12-20

Family

ID=8227753

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25369A MA26573A1 (fr) 1997-12-05 1998-12-04 Composes agonistes ou antagonistes du recepteur de l'orphanine, procede de preparation et medicament les contenant

Country Status (29)

Country Link
US (1) US6043366A (fr)
JP (1) JP3366868B2 (fr)
KR (1) KR19990062800A (fr)
CN (1) CN1118467C (fr)
AR (1) AR016428A1 (fr)
AT (1) ATE212635T1 (fr)
AU (1) AU744338B2 (fr)
BR (1) BR9805297B1 (fr)
CA (1) CA2255171C (fr)
CO (1) CO4990965A1 (fr)
CZ (1) CZ399698A3 (fr)
DE (1) DE69803653T2 (fr)
DK (1) DK0921125T3 (fr)
ES (1) ES2170446T3 (fr)
HR (1) HRP980613A2 (fr)
HU (1) HUP9802807A3 (fr)
ID (1) ID21413A (fr)
IL (1) IL127399A0 (fr)
MA (1) MA26573A1 (fr)
NO (1) NO312161B1 (fr)
NZ (1) NZ333159A (fr)
PE (1) PE135299A1 (fr)
PL (1) PL330062A1 (fr)
PT (1) PT921125E (fr)
SG (1) SG71173A1 (fr)
TR (1) TR199802520A2 (fr)
TW (1) TW408123B (fr)
YU (1) YU55198A (fr)
ZA (1) ZA9811128B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0997464B1 (fr) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanones utiles comme agonistes du récepteur orl1
JP3989247B2 (ja) * 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
CA2454785C (fr) * 2001-07-23 2010-09-07 Banyu Pharmaceutical Co., Ltd. Derive de 4-oxoimidazolidine-2-spiropiperidine
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
AU2003268512A1 (en) * 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2004058727A1 (fr) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite
ZA200510329B (en) * 2003-05-23 2007-04-25 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
RU2006117368A (ru) * 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные триазаспиропипередина, предназначенные для применения в качестве ингибиторов glyt-1 при лечении неврологических и психоневрологических нарушений
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CN101146801A (zh) * 2005-03-22 2008-03-19 霍夫曼-拉罗奇有限公司 新型的dpp-iv抑制剂的盐和多晶型物
WO2007149873A2 (fr) * 2006-06-20 2007-12-27 Wyeth Inhibiteurs du canal potassique kv1.5
CN103202840B (zh) * 2006-11-28 2015-02-11 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
CN101622241B (zh) 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
EP2150552B1 (fr) * 2007-04-09 2013-01-02 Janssen Pharmaceutica NV Dérivés de 1,3,8-trisubstitué-1,3,8-triaza-spiro[4.5]décan-4-one utilisés comme ligands du récepteur orl-i dans le traitement de l'anxiété et de la dépression
PA8801401A1 (es) * 2007-10-25 2009-05-15 Janssen Pharmaceutica Nv Arilindenopirimidinas y su uso como adenosina a2a
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
WO2010037081A1 (fr) * 2008-09-29 2010-04-01 Palatin Technologies, Inc. Composés de spiropipéridine spécifiques du récepteur de la mélanocortine
WO2010147776A1 (fr) 2009-06-16 2010-12-23 Merck Sharp & Dohme Corp. 1,3,8-triazaspiro[4,5]décane-2,4-diones substituées
CN107849044B (zh) * 2015-07-03 2021-06-25 豪夫迈·罗氏有限公司 作为ddr1抑制剂的三氮杂-螺癸酮类化合物
US20230357168A1 (en) * 2022-04-15 2023-11-09 The Chinese University Of Hong Kong Carbobicyclic nucleosides for treatment of viral infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3238216A (en) * 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
JPS51100084A (fr) * 1975-02-28 1976-09-03 Yoshitomi Pharmaceutical
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
GB1486546A (en) * 1975-02-28 1977-09-21 Yoshitomo Pharma Ind Ltd 4,4-diphenyl-cyclohexylpiperidine compounds and analogues thereof
JPS5934713B2 (ja) * 1976-01-05 1984-08-24 ウェルファイド株式会社 脂環式誘導体
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
GR73633B (fr) * 1980-03-10 1984-03-26 Janssen Pharmaceutica Nv
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
ATE67769T1 (de) * 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
CA2226058C (fr) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag Derives de substitution en 8 de 1,3,8-triazaspiro[4.5]decan-4-one

Also Published As

Publication number Publication date
DE69803653D1 (de) 2002-03-14
DK0921125T3 (da) 2002-05-13
CN1222521A (zh) 1999-07-14
HRP980613A2 (en) 1999-08-31
AU744338B2 (en) 2002-02-21
ZA9811128B (en) 1999-06-07
TR199802520A3 (tr) 1999-06-21
AR016428A1 (es) 2001-07-04
JP3366868B2 (ja) 2003-01-14
IL127399A0 (en) 1999-10-28
ATE212635T1 (de) 2002-02-15
CO4990965A1 (es) 2000-12-26
NO985684L (no) 1999-06-07
HUP9802807A2 (hu) 1999-08-30
CA2255171C (fr) 2009-09-29
HUP9802807A3 (en) 2000-01-28
CN1118467C (zh) 2003-08-20
TW408123B (en) 2000-10-11
DE69803653T2 (de) 2002-08-29
NO985684D0 (no) 1998-12-04
TR199802520A2 (xx) 1999-06-21
JPH11228575A (ja) 1999-08-24
HU9802807D0 (en) 1999-02-01
CZ399698A3 (cs) 1999-06-16
AU9608798A (en) 1999-06-24
YU55198A (sh) 2001-12-26
BR9805297B1 (pt) 2010-07-13
US6043366A (en) 2000-03-28
SG71173A1 (en) 2000-03-21
PE135299A1 (es) 2000-01-18
ES2170446T3 (es) 2002-08-01
ID21413A (id) 1999-06-10
BR9805297A (pt) 2000-02-01
NZ333159A (en) 2000-06-23
PL330062A1 (en) 1999-06-07
KR19990062800A (ko) 1999-07-26
NO312161B1 (no) 2002-04-02
CA2255171A1 (fr) 1999-06-05
PT921125E (pt) 2002-06-28

Similar Documents

Publication Publication Date Title
FR2786179B1 (fr) Composes quaternaires de piperidine antagonistes du recepteur ccr-3, composition pharmaceutique les contenant, leur utilisation et leur preparation
MA24361A1 (fr) Procede pouyr la preparation d'antagonistes de recepteur de vitronectine
HUP9603298A3 (en) Heterocyclic compounds having tachykinin receptor antagonist activity, their preparation, and their use for the preparation of pharmaceutical compositions
MA23768A1 (fr) Composes agonistes et antagonistes des oestrogenes et compositions les contenant
FR2732017B1 (fr) Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
EP1047425A4 (fr) Antagonistes du recepteur de l'integrine
FR2785902B1 (fr) 4-aroylpiperidines antagonistes du recepteur du ccr-3, compositions pharmaceutiques les contenant, procede pour les utiliser et les preparer
EP1140066A4 (fr) Composes et compositions antagonistes de recepteurs de h 2? nitroses et nitrosyles et procedes d'utilisation
EP1299362A4 (fr) Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci
IT1289532B1 (it) Composti, di cloridrato di paroxetina e procedimenti per la loro preparazione
PL327919A1 (en) Antagonists of vitronectin receptors
ZA98691B (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
HUP9900019A3 (en) Use of human cb2 receptor agonist indole derivatives for preparing immunomodulating drugs, new cb2 receptor agonist compounds and pharmaceutical compositions containing them
HUP0102658A3 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
HUP0103840A3 (en) New substituted pyperidine-derivatives for nociceptin receptor orl-1, pharmaceutical compositions containing them and their use
FI951265A7 (fi) Ihmisen NK3-reseptoreille selektiivisiä antagonistiyhdisteitä ja niiden käyttö lääkeaineina ja dioagnostisina aineina
NO302071B1 (no) Substituerte 1,2,3,4-tetrahydroisokinoliner med angiotensin II reseptorantagonistegenskaper, farmasöytisk preparat inneholdende slike forbindelser, samt anvendelse av dem
MA25829A1 (fr) Composes de carboxamide et leur utilisation en tant qu'antagonistes de recepteur de cby ii humain
IL118325A0 (en) Integrin receptor antagonists and pharmaceutical compositions containing them
ID16742A (id) Antagonis reseptor endotelin
MA26547A1 (fr) Composes nouveaux, antagonistes des recepteurs de vitronectine, et compositions pharmaceutiques les contenant.
FR2740134B1 (fr) Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
MA26644A1 (fr) Derives de 1,7, diaza-spiro (3,5) nonane, procede de preparation et medicament les contenant
IS4597A (is) Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them